Scarica l'app Stockscreener
94.65
0.86%
-0.82
Dopo l'orario di chiusura:
94.00
-0.65
-0.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$95.47
Aprire:
$94.95
Volume 24 ore:
1.11M
Relative Volume:
0.67
Capitalizzazione di mercato:
$18.84B
Reddito:
$5.14B
Utile/perdita netta:
$1.29B
Rapporto P/E:
14.78
EPS:
6.4034
Flusso di cassa netto:
$1.33B
1 W Prestazione:
-3.24%
1M Prestazione:
+4.45%
6M Prestazione:
+3.69%
1 anno Prestazione:
+60.51%
Intervallo 1D:
$93.63
$95.20
Intervallo di 1 settimana:
$93.63
$98.70
Portata 52W:
$57.77
$112.29
Incyte Corp Stock (INCY) Company Profile
Nome
Incyte Corp
Settore
Industria
Telefono
(302) 498-6700
Indirizzo
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
94.65 | 18.84B | 5.14B | 1.29B | 1.33B | 6.4034 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2026-02-05 | Iniziato | H.C. Wainwright | Buy |
| 2026-01-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-10-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Iniziato | Barclays | Overweight |
| 2025-06-16 | Aggiornamento | Stifel | Hold → Buy |
| 2025-03-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-18 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Iniziato | UBS | Neutral |
| 2024-10-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-10-01 | Iniziato | Wolfe Research | Outperform |
| 2024-09-18 | Downgrade | Truist | Buy → Hold |
| 2024-07-02 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Iniziato | Deutsche Bank | Hold |
| 2024-04-23 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Iniziato | Jefferies | Buy |
| 2024-02-14 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-11-21 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-25 | Iniziato | Citigroup | Buy |
| 2023-05-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Aggiornamento | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Iniziato | Piper Sandler | Overweight |
| 2022-08-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-07-28 | Iniziato | Wells Fargo | Equal Weight |
| 2022-02-09 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-07-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Iniziato | Truist | Buy |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-06-16 | Iniziato | The Benchmark Company | Hold |
| 2020-05-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Ripresa | William Blair | Outperform |
| 2020-03-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Ripresa | BofA/Merrill | Neutral |
| 2020-01-03 | Reiterato | BMO Capital Markets | Market Perform |
| 2020-01-03 | Downgrade | Mizuho | Buy → Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-10-03 | Iniziato | Mizuho | Buy |
| 2019-09-12 | Iniziato | BMO Capital Markets | Market Perform |
| 2019-09-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Iniziato | Credit Suisse | Neutral |
| 2019-05-03 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Iniziato | Stifel | Hold |
| 2019-04-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Aggiornamento | William Blair | Mkt Perform → Outperform |
Mostra tutto
Incyte Corp Borsa (INCY) Ultime notizie
Incyte gears up to report Q1 earnings: What can investors expect? - MSN
Incyte, BNY Mellon, Quantum-Si, Jabil, Levi Shock - TipRanks
Munich Reinsurance Co Stock Corp in Munich Invests $6.07 Million in Incyte Corporation $INCY - MarketBeat
Incyte Corporation $INCY Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
FDA calls out Incyte’s Niktimvo efficacy claims on branded website - Medical Marketing and Media
Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect? - The Globe and Mail
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Q1 Preview: The Growth Story Remains Intact (NASDAQ:INCY) - Seeking Alpha
Ruffer LLP Has $2.51 Million Holdings in Incyte Corporation $INCY - MarketBeat
Australia clears first chemo-free option for relapsed follicular lymphoma - Stock Titan
Incyte (INCY) Stock Analysis | Incyte Corp Posts 8.5% EPS Miss Vs Consensus ViewsMost Discussed Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Incyte Corporation $INCY Stock Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank - MarketBeat
31,459 Shares in Incyte Corporation $INCY Bought by CPC Advisors LLC - MarketBeat
INCY Financials: Income Statement, Balance Sheet & Cash Flow | Incyte Corp - Stock Titan
Incyte president, R&D head sells $1.8m in stock, acquires $1.2m in shares - Investing.com
INCYTE CORP (INCY) executive exercises options and sells 18,667 shares - Stock Titan
Incyte (INCY) to Present Phase 3 Tafasitamab Study Results at AS - GuruFocus
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 Americ - The National Law Review
Incyte to present tafasitamab lymphoma study results at ASCO - Investing.com
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire
Incyte discloses new TYK2 and/or JAK1 inhibitors - BioWorld News
Incyte (INCY) Projected to Post Earnings on Tuesday - MarketBeat
Assetmark Inc. Raises Holdings in Incyte Corporation $INCY - MarketBeat
Incyte to Report Q1 Results on April 28 - MyChesCo
Adagene and Incyte Partner to Develop Colorectal Cancer Therapy - HarianBasis.co
Adagene (ADAG) Partners With Incyte (INCY) to Evaluate Combination Therapy for Colorectal Cancer - Insider Monkey
Assessing Incyte (INCY) Valuation As Recent Returns Send Mixed Signals - Yahoo Finance
Here's Why Incyte (INCY) is a Strong Value Stock - Yahoo Finance
Incyte Corp. (NASDAQ:INCY) Presents a Compelling Value Investment Case - ChartMill
RBC Capital Lifts PT on Incyte Corporation (INCY) to $95 From $92 - Insider Monkey
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCYTE (NASDAQ: INCY) CEO granted 125,000 performance-based common shares - Stock Titan
INCYTE (INCY) R&D president earns 27,892 performance shares in equity award - Stock Titan
Incyte (NASDAQ: INCY) CMO earns 39,049 performance-based share award - Stock Titan
INCY (NASDAQ: INCY) Form 144 lists 18,667-share option exercise and prior sales - Stock Titan
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Shares Dip as Major Investor Reduces Stake - National Today
Incyte Corporation $INCY Holdings Lowered by Massachusetts Financial Services Co. MA - MarketBeat
Do Options Traders Know Something About Incyte Stock We Don't? - Yahoo Finance
INCY Reiterates by HC Wainwright & Co. -- Price Target Maintained at $135 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on hidradenitis drug - Investing.com
Incyte's (INCY) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
28,383 Shares in Incyte Corporation $INCY Purchased by Monument Capital Management - MarketBeat
Here's What to Expect From Incyte’s Next Earnings Report - Barchart.com
Robeco Institutional Asset Management B.V. Increases Stake in Incyte Corporation $INCY - MarketBeat
Beacon Harbor Wealth Advisors Boosts Incyte Corporation Holdings - National Today
INCYTE CORP (NASDAQ:INCY) Presents a High-Growth Momentum Breakout Setup - ChartMill
Q4 2025 Incyte Corp Earnings Call Transcript - GuruFocus
Incyte Corp stock: What investors should know about its biotech potential now - AD HOC NEWS
Incyte to Report First Quarter 2026 Financial Results - National Today
Incyte Corp Azioni (INCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.01%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):